Immune-mediated necrotizing myopathy; [Immunvermittelte nekrotisierende Myopathie]

被引：0
作者：
Bergua C. [1 ,2 ]
Chiavelli H. [1 ,2 ]
Simon J.P. [3 ]
Boyer O. [1 ,2 ,4 ]
Jouen F. [1 ,4 ]
Stenzel W. [5 ]
Martinet J. [1 ,2 ,4 ]
机构：
[1] Normandie University, IRIB, Rouen
[2] INSERM, U905, Rouen
[3] Department of Neuropathology, Caen University Hospital, Caen
[4] Department of Immunology, Rouen University Hospital, 22 bd Gambetta, Rouen
[5] Department of Neuropathology, Charité – Universitätsmedizin, Berlin
来源：
Zeitschrift für Rheumatologie | 2016年 / 75卷 / 2期
关键词：
Autoantibodies; Autoimmune disease; Myositis; Pathophysiology; Statins;
D O I：
10.1007/s00393-015-0029-3
中图分类号：
学科分类号：
摘要：
Background: Immune-mediated necrotizing myopathy (IMNM) is a newly identified subgroup of idiopathic inflammatory myopathies. It is defined as a rare and severe disease, with symmetrical and proximal muscle weakness and a characteristic histology. An autoimmune aspect of IMNM is suggested by its association with autoantibodies directed against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the majority of patients. Statin use is strongly associated with anti-HMGCR-positive IMNM. The pathophysiological mechanisms of this disease are still poorly understood, and as a result, no therapeutic strategy has been validated to date. Objective: The aim of this article is to provide an overview of the current knowledge about epidemiology, clinical features, and pathophysiology of IMNM, as well as treatment strategies. Results and conclusion: IMNM is a subject of widespread interest, with quick and meaningful advances being made. In recent years, huge progress has been made in terms of diagnosis and patient management. However, the understanding of pathophysiological mechanisms and treatment strategies still requires further investigation. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：151 / 156
页数：5
相关论文
共 38 条
  • [1] Dalakas M.C., Inflammatory muscle diseases, N Engl J Med, 372, pp. 1734-1747, (2015)
  • [2] Hoogendijk J.E., Et al., 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands, Neuromuscul Disord, 14, pp. 337-345, (2004)
  • [3] Christopher-Stine L., Et al., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis Rheum, 62, pp. 2757-2766, (2010)
  • [4] Hengstman G.J.D., Et al., Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy, Ann Rheum Dis, 65, pp. 1635-1638, (2006)
  • [5] Liang C., Needham M., Necrotizing autoimmune myopathy, Curr Opin Rheumatol, 23, pp. 612-619, (2011)
  • [6] Reeves W.H., Nigam S.K., Blobel G., Human autoantibodies reactive with the signal-recognition particle, Proc Natl Acad Sci U S A, 83, pp. 9507-9511, (1986)
  • [7] Mastaglia F.L., Phillips B.A., Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria, Rheum Dis Clin North Am, 28, pp. 723-741, (2002)
  • [8] Rouster-Stevens K.A., Pachman L.M., Autoantibody to signal recognition particle in African American girls with juvenile polymyositis, J Rheumatol, 35, pp. 927-929, (2008)
  • [9] Alshehri A., Choksi R., Bucelli R., Pestronk A., Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology, Neurol Neuroimmunol Neuroinflamm, 2, (2015)
  • [10] Drouot L., Et al., Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies, Arthritis Res Ther, 16, (2014)
1234